Figure 5. Model output for the Uganda HMM programme using a hypothetical ‘ideal’ antimalarial from a provider perspective.

These results indicate that even if an ‘ideal’ antimalarial is introduced into HMM, the settings where HMM is cost-effective remain limited to medium and high transmission areas, unless the probability of receiving appropriate care is zero.